NinaDelaneyWagner-JohnstonMD

Oncology • Baltimore, MD

Assistant Professor, Internal Medicine, Washington University School of Medicine

Join to view full profile

Dr. Wagner-Johnston is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wagner-Johnston's full profile

Already have an account?

Office
401 North Broadway Street
Weinberg BLDG
Baltimore, MD 21287
Phone+1 410-955-8964

Fax+1 410-367-2194

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2005 - 2008
University of ChicagoResidency, Internal Medicine, 2003 - 2005
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2003

Certifications & Licensure

DC State Medical License 2022 - 2026
MD State Medical License 2005 - 2025
PA State Medical License 2024 - 2024
MO State Medical License 2008 - 2016
IL State Medical License 2003 - 2006

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Study of Blood and Tissue Samples From Patients With Aggressive Non-Hodgkin B-Cell Lymphoma or Hodgkin Lymphoma Start of enrollment: 2009 Aug 01
Completed
Evaluate the Efficacy of Armodafinil for Patients With B-cell Lymphoma and Severe Fatigue Start of enrollment: 2010 Mar 01
Withdrawn
Not Applicable
Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma Start of enrollment: 2012 Sep 01
Active, not recruiting
Phase 2
Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma Start of enrollment: 2012 Jul 01
Terminated
Phase 1
Study of Rituximab and Brentuximab Vedotin for Relapsed Classical Hodgkin Lymphoma Start of enrollment: 2014 Jun 01
Terminated
Phase 1
Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion Start of enrollment: 2014 Aug 06
Terminated
Phase 2
Brentuximab Vedotin and Lenalidomide for Relapsed or Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2014 Sep 18
Completed
Phase 1
Falls Risk Questionnaire in Older Adults With Cancer Start of enrollment: 2014 Aug 01
Completed
Perspectives on Bone Marrow Donors Who Donate for Their Parent Start of enrollment: 2016 Dec 06
Completed
Non-Invasive Neurosensory Testing For Chemotherapy-Induced Peripheral Neuropathy Start of enrollment: 2017 Nov 29
Completed
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma Start of enrollment: 2019 Dec 13
Active, not recruiting
Phase 2
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL Start of enrollment: 2022 Feb 15
Withdrawn
Phase 1
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Improved Overall Survival with Checkpoint Inhibition and Allogeneic Transplantation in Relapsed Hodgkin Lymphoma.
Nadeem Tabbara, Marianna L Zahurak, Cole Sterling, Iris Margalit Trutzer, Jaroslaw Jedrych
Blood Advances. 2024-12-18
1 citations
Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101.
Tracy T Batchelor, Sharmila Giri, Amy S Ruppert, Susan M Geyer, Scott E Smith
Blood Advances. 2024-06-25
10 citations
TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers.
Tushar D Nichakawade, Jiaxin Ge, Brian J Mog, Bum Seok Lee, Alexander H Pearlman
Nature. 2024-04-01

Abstracts/Posters

A Phase IB Study of Blinatumomab (blina) in Patients with B Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or M...
Nina D. Wagner-Johnston, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pat...
Nina D. Wagner-Johnston, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Allogenic Stem Cell Transplantation for Secondary CNS Lymphoma: A Retrospective Review of 21 Patients
Nina D. Wagner-Johnston, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B...
Nina D. Wagner-Johnston, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagen...
Nina D. Wagner-Johnston, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Join now to see all

Lectures

Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/ Waldenstrom's Macroglobulinemia
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: An Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial o...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Making Strides in the Treatment of B-Cell Malignancies: Keeping Up With New Data and Practice Recommendations
60th American Society of Hematology Annual Meeting - 11/30/2018
Join now to see all

Press Mentions

Treatment Options in MCL: What Are the Best Practices?September 12th, 2024
Pain PointersJune 1st, 2021
Dual Expression of MYC, BCL2 Associated with Poorer Outcomes in DLBCLMay 26th, 2017